Shekhat Denil Nanji Buys 50,000 Shares of MIRA Pharmaceuticals

On June 12, 2026, Shekhat Denil Nanji, an insider at MIRA Pharmaceuticals, Inc. (NasdaqCM: MIRA), purchased 50,000 shares. This transaction comes as the stock was trading around $0.93.

Insider Buying and Selling at MIRA Pharmaceuticals, Inc.

Several insiders, including Shekhat Denil Nanji, have recently acquired shares of MIRA Pharmaceuticals. On June 12, 2026, insiders Edward Clouston Macpherson, Matthew Paul Del Giudice, and Matthew Pratt Whalen each bought 50,000 shares. Earlier, on December 17, 2025, CEO Erez Aminov purchased 3,155,170 shares, indicating strong insider interest.

Other Institutional Activity in MIRA Pharmaceuticals

Institutional investors have also shown activity in MIRA Pharmaceuticals. Vanguard Capital Management LLC added 693,912 shares, bringing its total to 693,912 shares valued at approximately $742,486. Geode Capital Management, LLC increased its stake by 18,012 shares, ending with 290,890 shares worth about $311,251. Meanwhile, BlackRock, Inc. raised its holdings by 2,577 shares, totaling 112,346 shares valued at $120,210. Conversely, Suncoast Equity Management reduced its position by 12,644 shares, holding 90,645 shares worth around $96,990.

MIRA Pharmaceuticals Stock Snapshot

Shares of MIRA Pharmaceuticals (NasdaqCM: MIRA) are trading near $0.93. The company has a market capitalization of approximately $39.16 million. It operates with a forward P/E ratio that isn't meaningful due to its lack of profitability. The stock's 52-week range spans from a low of $0.90 to a high of $2.45. MIRA's 50-day moving average stands at $1.02, with a 200-day moving average of $1.28. The company maintains a robust current ratio of 82.16 and a quick ratio of 81.97.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc., based in Miami, Florida, is a pre-clinical-stage pharmaceutical company focusing on neuroscience. It holds exclusive rights in the U.S., Canada, and Mexico for Ketamir-2, a next-generation oral NMDA receptor modulator that has completed a Phase 1 clinical trial. The company is also developing MIRA-55, an oral pharmaceutical marijuana product for anxiety and cognitive decline, and SKNY-1, aimed at obesity and nicotine dependence. MIRA Pharmaceuticals was incorporated in 2020 and is led by CEO Erez Aminov.

Bottom Line

Insider buying at MIRA Pharmaceuticals, including the recent acquisition by Shekhat Denil Nanji, reflects a notable level of confidence in the company's future. Investors often track these transactions for insights into management's outlook. It's essential to remember that these insider transactions are disclosed after the fact and may not represent current positions.